Structured evidence table for Glucosamine Knee Osteoarthritis Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Glucosamine Knee Osteoarthritis Meta-Analysis | Background This umbrella review synthesizes evidence from systematic reviews and meta-analyses evaluating the efficacy and safety of diverse curcumin formulations in the treatment of osteoarthritis (OA). | 1 | Shi C (2026) | Efficacy and safety of different curcumin formulations in osteoarthritis: an umbrella review of systematic reviews. |
| Glucosamine Knee Osteoarthritis Meta-Analysis | Conclusion Curcumin-based interventions show promise for OA symptom management, with efficacy signals comparable to NSAIDs and appear to have a more favorable tolerability profile in the available studies, while addressing bioavailability challenges. | 1 | Shi C (2026) | Efficacy and safety of different curcumin formulations in osteoarthritis: an umbrella review of systematic reviews. |
| Glucosamine Knee Osteoarthritis Meta-Analysis | The objective is to assess curcumin's therapeutic potential and inform future formulation development. | 1 | Shi C (2026) | Efficacy and safety of different curcumin formulations in osteoarthritis: an umbrella review of systematic reviews. |
| Glucosamine Knee Osteoarthritis Meta-Analysis | Background Chondroitin sulfate, alone or associated with glucosamine (CS/CS+GLU), is an effective knee osteoarthritis (KOA) treatment, with fewer adverse effects (AEs) than non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase 2 inhibitors (COXIBs). | 4 | Rubio-Terrés C (2026) | Cost-Effectiveness of Chondroitin Sulphate (with or without Glucosamine) Prescription in the Treatment of Knee Osteoarthritis Compared to NSAIDs and COXIBs. |
| Glucosamine Knee Osteoarthritis Meta-Analysis | AEs frequency, associated utilities loss and managing cost were obtained from medical literature and Spanish sources. | 4 | Rubio-Terrés C (2026) | Cost-Effectiveness of Chondroitin Sulphate (with or without Glucosamine) Prescription in the Treatment of Knee Osteoarthritis Compared to NSAIDs and COXIBs. |
| Glucosamine Knee Osteoarthritis Meta-Analysis | Conclusion The improved tolerability of CS/CS+GLU versus NSAIDs/COXIBs is expected to prevent thousands of AEs and generate considerable savings for the NHS, making it cost-effective treatment. | 4 | Rubio-Terrés C (2026) | Cost-Effectiveness of Chondroitin Sulphate (with or without Glucosamine) Prescription in the Treatment of Knee Osteoarthritis Compared to NSAIDs and COXIBs. |
| Glucosamine Knee Osteoarthritis Meta-Analysis | Purpose To estimate the CS/CS+GLU cost-effectiveness versus NSAIDs/COXIBs, due to the avoidance of mild-moderate or severe gastrointestinal AEs (GIAE), ischemic heart disease (IHD), acute kidney insufficiency (AKI), chronic kidney failure (CKF) and ischemic stroke (IS) from the Spanish National Health System (NHS) perspective. | 4 | Rubio-Terrés C (2026) | Cost-Effectiveness of Chondroitin Sulphate (with or without Glucosamine) Prescription in the Treatment of Knee Osteoarthritis Compared to NSAIDs and COXIBs. |
Source documents